Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2006 1
2008 1
2011 3
2012 2
2013 1
2014 3
2015 1
2016 6
2017 2
2018 1
2019 1
2020 5
2021 10
2022 8
2023 7
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

44 results

Results by year

Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
Page 1
Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trial.
Monk BJ, Toita T, Wu X, Vázquez Limón JC, Tarnawski R, Mandai M, Shapira-Frommer R, Mahantshetty U, Del Pilar Estevez-Diz M, Zhou Q, Limaye S, Godinez FJR, Oppermann Kussler C, Varga S, Valdiviezo N, Aoki D, Leiva M, Lee JY, Sulay R, Kreynina Y, Cheng WF, Rey F, Rong Y, Ke G, Wildsmith S, Lloyd A, Dry H, Tablante Nunes A, Mayadev J. Monk BJ, et al. Lancet Oncol. 2023 Dec;24(12):1334-1348. doi: 10.1016/S1470-2045(23)00479-5. Lancet Oncol. 2023. PMID: 38039991 Clinical Trial.
Chemoradiotherapy included 45 Gy external beam radiotherapy at 5 fractions per week concurrent with intravenous cisplatin (40 mg/m(2)) or carboplatin (area under the concentration-time curve 2) once weekly for 5 weeks, followed by image-guided brachytherapy (high-dose rate …
Chemoradiotherapy included 45 Gy external beam radiotherapy at 5 fractions per week concurrent with intravenous cisplatin (40 mg/m(2) …
The Effects of Agave Fructans in a Functional Food Consumed by Patients with Irritable Bowel Syndrome with Constipation: A Randomized, Double-Blind, Placebo-Controlled Trial.
Camacho-Díaz BH, Arenas-Ocampo ML, Osorio-Díaz P, Jiménez-Aparicio AR, Alvarado-Jasso GM, Saavedra-Briones EV, Valdovinos-Díaz MÁ, Gómez-Reyes E. Camacho-Díaz BH, et al. Nutrients. 2023 Aug 10;15(16):3526. doi: 10.3390/nu15163526. Nutrients. 2023. PMID: 37630717 Free PMC article. Clinical Trial.
Irritable bowel syndrome displays three different subtypes: constipation (IBS-C), diarrhea (IBS-D), and mixed (IBS-M). Treatment with dietary fiber is used, with consideration given both to the chemical composition of the fiber and to the different subtypes of IBS. ...
Irritable bowel syndrome displays three different subtypes: constipation (IBS-C), diarrhea (IBS-D), and mixed (IBS-M). Treatment with …
Animal-to-human transmission of Mycobacterium pinnipedii.
Macedo R, Isidro J, Gomes MC, Botelho A, Albuquerque T, Sogorb A, Bernardino R, Fernandes TL, Mourato T, Durval M, Gomes JP. Macedo R, et al. Eur Respir J. 2020 Dec 17;56(6):2000371. doi: 10.1183/13993003.00371-2020. Print 2020 Dec. Eur Respir J. 2020. PMID: 32732327 Free article. No abstract available.
Evidence-based guidelines for the use of tracheostomy in critically ill patients.
Raimondi N, Vial MR, Calleja J, Quintero A, Cortés A, Celis E, Pacheco C, Ugarte S, Añón JM, Hernández G, Vidal E, Chiappero G, Ríos F, Castilleja F, Matos A, Rodriguez E, Antoniazzi P, Teles JM, Dueñas C, Sinclair J, Martínez L, von der Osten I, Vergara J, Jiménez E, Arroyo M, Rodríguez C, Torres J, Fernandez-Bussy S, Nates JL; FEPIMCTI and LACCTIN. Raimondi N, et al. J Crit Care. 2017 Apr;38:304-318. doi: 10.1016/j.jcrc.2016.10.009. Epub 2016 Oct 20. J Crit Care. 2017. PMID: 28103536
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group.
Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M, Parulekar W. Moore MJ, et al. J Clin Oncol. 2023 Oct 20;41(30):4714-4720. doi: 10.1200/JCO.22.02770. J Clin Oncol. 2023. PMID: 37847995 Clinical Trial.
Complementary feeding practices and their association with adiposity indicators at 12 months of age.
Rodríguez-Cano AM, Mier-Cabrera J, Rodríguez-Hernández C, Allegre-Dávalos AL, Muñoz-Manrique C, Perichart-Perera O. Rodríguez-Cano AM, et al. J Dev Orig Health Dis. 2021 Oct;12(5):780-787. doi: 10.1017/S2040174420001038. Epub 2020 Nov 23. J Dev Orig Health Dis. 2021. PMID: 33222718

During the first 6 M, 28.3% (n = 30) of the infants received EBF. Early CF (<4 M) was present in 26.4% (n = 28) of the infants. ...Starting CF < 4 M was the main factor associated with a higher WC at 12 M. Unhealthy infant feeding practices, such

…
During the first 6 M, 28.3% (n = 30) of the infants received EBF. Early CF (<4 M) was present in 26.4% (n = 28) of the infa …
Metastasis to the oral and maxillofacial region. A systematic review.
Labrador AJP, Marin NRG, Valdez LHM, Sanchez KBT, Zabarburu W, Ibazetta KAR, Garcia AER, Cabezas DM, Romero L, Conte AM, Wright JM. Labrador AJP, et al. J Stomatol Oral Maxillofac Surg. 2022 Oct;123(5):e474-e483. doi: 10.1016/j.jormas.2021.12.009. Epub 2021 Dec 20. J Stomatol Oral Maxillofac Surg. 2022. PMID: 34933137
Development and validation of anthropometric-based fat-mass prediction equations using air displacement plethysmography in Mexican infants.
Rodríguez-Cano AM, Piña-Ramírez O, Rodríguez-Hernández C, Mier-Cabrera J, Villalobos-Alcazar G, Estrada-Gutierrez G, Cardona-Pérez A, Coronado-Zarco A, Perichart-Perera O. Rodríguez-Cano AM, et al. Eur J Clin Nutr. 2023 Jul;77(7):748-756. doi: 10.1038/s41430-023-01285-9. Epub 2023 Apr 13. Eur J Clin Nutr. 2023. PMID: 37055482 Free PMC article.
There were no significant differences between predicted vs measured FM (1 M: 0.62 vs 0.6; 3 M: 1.2 vs 1.35; 6 M: 1.65 vs 1.76 kg; p > 0.05). Bias were: 1 M -0.021 (95%CI: -0.050 to 0.008), 3 M: 0.014 (95%CI: 0.090-0.195), 6 M: 0.108 (9 …
There were no significant differences between predicted vs measured FM (1 M: 0.62 vs 0.6; 3 M: 1.2 vs 1.35; 6 M: 1.65 v …
Management of a Pregnant Woman With Fibromuscular Dysplasia.
Berra E, Dominiczak AF, Touyz RM, Pierard S, Hammer F, Rossi GP, Micali RG, Staessen JA, Bursztyn M, Kahan T, Persu A. Berra E, et al. Hypertension. 2018 Apr;71(4):540-547. doi: 10.1161/HYPERTENSIONAHA.118.10819. Epub 2018 Feb 26. Hypertension. 2018. PMID: 29483231 Free article. No abstract available.
44 results